Author details

Full Name

Julie M Decker

Affiliation

ORCID

Career Start Year

1991

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
30718403	CD4 receptor diversity in chimpanzees protects against SIV infection.	Proc Natl Acad Sci U S A	2019
27412591	Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection.	J Virol	2016
25900654	Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.	mBio	2015
25707797	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.	Nature	2015
23123038	Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones.	Virology	2013
23468494	Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.	Journal of Virology	2013
23542380	Phenotypic properties of transmitted founder HIV-1.	Proc Natl Acad Sci U S A	2013
22031948	Broad and potent neutralizing antibody responses elicited in natural HIV-2 infection.	Journal of Virology	2012
22933274	Epitope mapping of broadly neutralizing HIV-2 human monoclonal antibodies.	Journal of Virology	2012
22505456	Efficient SIVcpz replication in human lymphoid tissue requires viral matrix protein adaptation.	Journal of Clinical Investigation	2012
22693447	Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.	PLoS Pathogens	2012
22693444	Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin Î±4Î²7.	PLoS Pathog	2012
22837215	Eastern chimpanzees, but not bonobos, represent a simian immunodeficiency virus reservoir.	J Virol	2012
23110705	Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome.	Retrovirology	2012
22190722	Generation of transmitted/founder HIV-1 infectious molecular clones and characterization of their replication capacity in CD4 T lymphocytes and monocyte-derived macrophages.	Journal of Virology	2012
21980282	Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections.	PLoS Pathog	2011
21849452	Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.	Journal of Virology	2011
21715507	Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins.	J Virol	2011
21835785	Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.	J Virol	2011
20003995	A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.	Virology	2010
20485520	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men.	PLoS Pathogens	2010
20352106	4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms.	PLoS ONE	2010
19193787	In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth.	Journal of Virology	2009
19748647	Effective activation alleviates the replication block of CCR5-tropic HIV-1 in chimpanzee CD4+ lymphocytes.	Virology	2009
19487424	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.	J Exp Med	2009
19298995	High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.	Virology	2009
19073717	Origin and biology of simian immunodeficiency virus in wild-living western gorillas.	Journal of Virology	2009
19019969	Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma.	Journal of Virology	2009
18490657	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection.	Proc Natl Acad Sci U S A	2008
18619974	Combinatorial optimization of a CD4-mimetic miniprotein and cocrystal structures with HIV-1 gp120 envelope glycoprotein.	Journal of Molecular Biology	2008
18094155	4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response.	Journal of Virology	2008
18815292	Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.	J Virol	2008
17097711	Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.	Virology	2007
17701860	Severe gastrointestinal disease due to HIV-1-seronegative AIDS.	Zeitschrift fur Gastroenterologie	2007
17409164	Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.	Journal of Virology	2007
17409160	Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.	J Virol	2007
17360739	Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.	J Virol	2007
17545188	Adaptation of HIV-1 to its human host.	Molecular Biology and Evolution	2007
17494082	Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees.	J Virol	2007
16780913	Ancestral and consensus envelope immunogens for HIV-1 subtype C.	Virology	2006
16971434	Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.	J Virol	2006
16699001	Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1.	J Virol	2006
17039602	A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.	Virology	2006
15893666	Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth.	Structure	2005
15613343	Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.	Journal of Virology	2005
15867093	Antigenic conservation and immunogenicity of the HIV coreceptor binding site.	J Exp Med	2005
16051804	Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies.	Journal of Virology	2005
15044802	Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.	Science	2004
15220433	Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.	J Virol	2004
15105117	Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription.	Antimicrob Agents Chemother	2004